News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Doubles Laboratory Space
BOULDER, Colo.—(July 12th, 2000)—Array BioPharma Inc., a drug discovery research company, today announced a major expansion that will increase its lab space from 25,000 to 50,000 square feet. This new facility, located in neighboring Longmont, Colorado, was built to accommodate Array’s growing number of Ph.D. chemists working on several new collaborations.

Array anticipates it will surpass 100 employees this month coincident with the celebration of its second anniversary. The Longmont facility contains state-of-the-art chemistry laboratories with preparative scale reactors and a fully equipped analytical suite.

“The rapid growth in demand for Array’s drug discovery products and services is being fueled by the emergence of new targets resulting from the genomics revolution,” says Robert E. Conway, Chief Executive Officer of Array BioPharma. “With this new state-of-the-art facility, we will provide a unique research environment for the growing number of world-class chemists entering our organization.”

This facility expansion will provide Array with the capacity to match the demands of a recently announced chemistry-based research agreement with Eli Lilly and Company, which will have up to 30 Array scientists working in collaboration with Lilly scientists on several drug discovery projects. It will also offer capacity for several other soon-to-be announced collaborations and will meet the increasing demands for custom synthesis and process research. To date, Array has announced several small molecule library agreements with companies including Celltech Chiroscience, Neurocrine and Tularik.

Array BioPharma, Inc., is a privately-held discovery research company providing research services in all aspects of chemistry, high-throughput screening, structural biology and information management. Array complements the experience of its researchers with proprietary drug discovery tools, including unique sets of building blocks called OptimersTM for automated lead explosion, pharmacophore-biased small molecule libraries, high-speed synthesis automation, X-ray crystallography and qualifying human drug metabolism assays.

For additional information, visit the company’s web site at www.arraybiopharma.com.